Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Open-Label Study Investigating the Tolerability, Safety, and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma

NCT05561374 is registered in ClinicalTrials.gov with Oblato, Inc. as lead sponsor.

NCT NCT05561374
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05561374 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Open-Label Study Investigating the Tolerability, Safety, and Pharmacokinetic Properties of Oral OKN-007 in Patients with Recurrent High-Grade Glioma
Lead sponsor
Oblato, Inc.
Phase
Phase 1
Overall status
Active, not recruiting
Start date
April 17, 2023
Completion date
June 30, 2025
Enrollment
16 (estimated)
Sites
4

Conditions

As the registry lists them; a condition with its own page is linked.

astrocytoma, glioblastoma multiforme, high-grade glioma, oligodendroglioma